The Use of Psychedelic Medicines to Treat Resistant Post Traumatic Stress Disorder: The Legal and Policy Implications
Research output: Contribution to conference › Other › peer-review
Details
| Original language | English |
|---|---|
| Publication status | Published - 25 Mar 2017 |
| Event | EMDR Association UK & Ireland Annual Conference 2017 - London Duration: 25 Mar 2017 → … |
Conference
| Conference | EMDR Association UK & Ireland Annual Conference 2017 |
|---|---|
| Period | 25/03/17 → … |
| Publication type | Research output: Contribution to conference › Other › peer-review |
|---|
Abstract
Psychedelic research into psychiatric disorders is slowly re-emerging after a near 40-year morass. The presentation touches on psychedelic research history, its near-complete prohibition from the early 1970s and recent rebirth. Current US trials of MDMA-assisted psychotherapy and medical marijuana for treatment-resistant PTSD are focussed on as are patent applications for nasal ketamine sprays for the acutely suicidal. The laws and regulatory procedures governing current clinical research and likely future licensing are considered.